MedTrace Logo

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

NCT03203304 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-06-10

No results posted yet for this study

Summary

External beam photon stereotactic body radiotherapy (SBRT) using a linear accelerator to a total dose of 40 Gy in 5 fractions delivered once daily with at least 48 hours between each fraction. SBRT treatment will be completed within a 21-day window. Starting within 14 days after completion of SBRT, intravenous nivolumab 240 mg will be given every 2 weeks as monotherapy or in combination with ipilimumab 1 mg/kg IV every 6 weeks.

Conditions

Interventions

DRUG

Nivolumab

240mg every two weeks by IV infusion

DRUG

Ipilimumab

1mg/kg every six weeks by IV infusion

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Chih-Yi Liao, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-25
Primary Completion
2019-03-13
Completion
2019-03-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03203304 on ClinicalTrials.gov